A Phase III trial of Macugen injection treatment for patients with diabetic macular edema (DME), a complication of chronic diabetes that causes blindness, showed maintained and expanded vision gains, it has been announced.
The study showed that 37% of patients treated with Macugen gained two lines of vision on an eye chart after 54 weeks, compared with 20% of patients given a placebo injection.
Safety results of the study showed that an increase in intraocular pressure was a common adverse effect of the Macugen injections. High pressure was noticed in 2.5 times more Macugen patients than placebo patients.
The multicentre, randomised, sham-controlled, double-masked study was conducted on 260 patients with DME from September 2005.